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Abstract Gp65 and gp55 are immunoglobulin superfamily
members produced by alternative splicing of the same gene
transcript, and originally identified as components of synaptic
membranes. A monoclonal antibody specific for gp65 and gp55
has been used to detect immunoreactive species in a wide range of
tissues. All immunoreactive species bind to concanavalin A and
deglycosylation studies show that in all tissues tested other than
brain the immunoreactive species are derived from gp55. HEK
cells transfected with gp65 or gp55 express different glycoforms
from brain showing that the pattern of glycosylation of these
molecules is dependent upon the cell type in which they are
expressed.
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1. Introduction
Gp65 and gp55 are two closely structurally related glyco-
proteins (apparent Mr 65 and 55 kDa respectively) originally
identi¢ed as components of synaptic membranes (SM) [1,2].
Gp65 and gp55 are recognised by a single monoclonal anti-
body (mab), SMgp65. The two glycoproteins show striking
di¡erences in regional, subcellular and cellular distribution,
and in developmental expression. Gp65 is most enriched in
post-synaptic densities (PSDs) prepared from adult rat fore-
brain whereas gp55 is virtually absent from this fraction [1].
The PSD is a specialised region of the membrane cytoskeleton
which both underlies and is attached to the post-synaptic
membrane. Gp65 is localised to subsets of predominantly
forebrain neurones whereas gp55 is present in all brain regions
[1]. Gp55 is expressed early in brain development reaching its
maximal level by postnatal days 10^12, whereas the level of
gp65 increases markedly during the second and third postna-
tal weeks, concomitant with the major period of synaptogen-
esis [3]. Sequencing studies show that gp65 and gp55 are novel
members of the immunoglobulin (Ig) superfamily which arise
by alternative splicing of the same gene transcript. They con-
tain a common sequence comprising two Ig domains, a single
transmembrane domain and a short intracellular domain [4].
Gp65 is distinguished from gp55 by the presence of a further
Ig domain at its N-terminus. The sequence data show that
both gp65 and gp55 contain six potential sites for N-glycosy-
lation. Enzymic deglycosylation with endoglycosidase H and
endoglycosidase F (endo-F) containing peptide-N glycosidase
F (PNGase F) shows that both glycoproteins contain high
mannose and complex oligosaccharides. Complete removal
of oligosaccharides with tri£uoromethane sulphonic acid or
endo-F/PNGase F lowers the apparent Mr of gp65 and
gp55 to 40 and 28 kDa respectively [2]. These results suggest
that several if not all of the six sites predicted from the se-
quence data are glycosylated in vivo.
Our original published data suggested that both glycopro-
teins are brain-speci¢c [1]. However, Northern blot data
shows that the 2.2 kb transcript which encodes gp55 is widely
distributed, whereas the 2.5 kb transcript which encodes gp65
is brain-speci¢c [4]. We have previously shown that gp55 gly-
coforms are present in liver [4]. Thus our aims here are: to
demonstrate that although gp65 is brain-speci¢c gp55 glyco-
forms are expressed in a wide range of tissues; to establish
that the pattern of gp55 glycoforms varies between tissues,
and, using gp65 and gp55 transfected HEK cells, to demon-
strate that the pattern of glycosylation of both molecules is
dependent upon the cell type in which they are expressed.
2. Materials and methods
2.1. Preparation of Triton X-100 solubilised membrane proteins
Triton X-100 solubilised membrane proteins from all tissues tested
were prepared from adult Wistar rats (postnatal age 13^15 weeks) as
follows. Immediately following removal from the animal all tissues
were homogenised in homogenising bu¡er: 25 mM Tris-HCl, pH
7.4, 500 mM NaCl containing the following protease inhibitors: anti-
pain, chymostatin, leupeptin and pepstatin all at a ¢nal concentration
of 1 mg/ml and phenylmethylsulphonyl £uoride (0.2 mM). The tissue
to bu¡er ratio was 5 ml bu¡er/g wet wt. tissue. The homogenate
(protein concentration 12^15 mg/ml bu¡er) was centrifuged at
100 000Ugav for 1 h, and the pellet resuspended in an equal volume
of homogenisation bu¡er containing 1% (v/v) Triton X-100. Follow-
ing incubation for 60 min at 4‡C the material was centrifuged as
above. The supernatant contained the Triton X-100 solubilised pro-
teins (protein concentration 4^5 mg/ml bu¡er). Thus about one third
of starting protein is present in the Triton X-100 solubilised fraction.
Protein samples were stored at 370‡C prior to further analysis.
2.2. Isolation of concanavalin A (Con A) binding glycoproteins
High mannose containing glycoproteins were isolated by binding to
Con A agarose beads as detailed by Gurd et al. [5]. The bound gly-
coproteins were eluted from the beads by boiling in Laemmli sample
bu¡er for 5 min.
2.3. Digestion with endo-F/PNGase F
Digestion was performed as described by the manufacturer of the
enzyme (Oxford GlycoSystems, Abingdon, UK). Membrane samples
(200 Wg) were denatured by boiling for 3 min in 0.5% (w/v) SDS
containing 2.5% L-mercaptoethanol followed by digestion with
endo-F/PNGase F (10 DGU/200 Wg protein) in incubation bu¡er
(20 mM sodium phosphate pH 7.5, 50 mM EDTA, 0.5% octylglyco-
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side, 0.1% SDS, 0.5% L-mercaptoethanol) at 37‡C for 18 h. Control
samples were digested in the absence of the enzyme mixture. Protease
inhibitors were included in all samples.
2.4. Gel electrophoresis and Western blotting
These were carried out as previously described ([2,6] and [7]). Pro-
teins were separated on 10% gels unless otherwise stated.
2.5. Immunodevelopment of Western blots
This was essentially as described by Willmott et al. [2]. Brie£y blots
were blocked in 5% (w/v) dried milk dissolved in phosphate-bu¡ered
saline (PBS) and incubated in mab SMgp65 overnight. After washing
four times in PBS containing 0.1% (v/v) Tween blots were incubated
in peroxidase-coupled rabbit anti-mouse IgG (DAKO) and visualised
using the ECL detection system.
2.6. Antibody production
Mab SMgp65 is secreted by a hybridoma cell line raised against a
synaptic membrane Con A binding fraction [1]. The antiserum speci¢c
for gp65 was obtained by a⁄nity puri¢cation of a rabbit polyclonal
antiserum raised against a recombinant protein encoding all three
gp65 Ig domains. Brie£y fusion protein encoding the gp65 speci¢c
domain was separated by SDS polyacrylamide gel electrophoresis
and electrophoretically transferred to nitrocellulose. The nitrocellulose
containing the bound gp65-speci¢c domain was blocked with 5% (v/v)
dried milk in PBS and incubated overnight in antiserum. The nitro-
cellulose was washed as for Western blots and gp65-speci¢c antiserum
eluted by incubation (5 min) in 0.2 M glycine, pH 2.8, containing
0.5 M NaCl. The small quantity of eluted gp65-speci¢c antiserum
was rapidly neutralised with saturated Tris.
2.7. Stable expression of gp65 and gp55 in HEK293 cells
This was as previously described [4].
3. Results
Immunodevelopment of a Western blot of Triton X-100
solubilised membrane proteins prepared from a range of tis-
sues with mab SMgp65 shows the presence of immunoreactive
species in all samples (Fig. 1). Tissues examined were liver,
kidney, muscle, stomach, spleen, testis, lung, heart and brain
(Fig. 1, lanes 1^9). None of the immunoreactive species de-
tected with mab SMgp65 were observed on blots developed in
the absence of primary antibody thus con¢rming the speci¢c-
ity of the antibody (results not shown). The di¡use nature of
the immunoreactive bands is attributable to microheterogene-
ity of oligosaccharide structure as we have previously dis-
cussed [1,2]. As expected brain shows the two immunoreactive
bands of apparent Mr 55 kDa and 65 kDa corresponding to
gp65 and gp55 (Fig. 1, lane 9). Although the immunoreactive
species detected in the other tissues are in the same molecular
weight range none are of identical Mr to gp65 and gp55. All
tissues tested contain an immunoreactive band of Mr 44 kDa
although this is a very minor immunoreactive component in
brain (Fig. 1, lower arrowheads). They also contain at least
one further immunoreactive species, in some cases (e.g. heart)
more, but the apparent Mr varies between tissues. Possible
overlap between di¡use bands makes it di⁄cult to unequivo-
cally identify the exact number of glycoforms present in each
tissue. However, the number of gp55 glycoforms does vary
between tissues, one major species being detected in brain
and at least four species in heart (Fig. 1, cf. lanes 9 and 8
respectively). Liver and muscle contain an immunoreactive
species of apparent Mr 61 kDa, i.e. intermediate between
that of gp65 and gp55 (Fig. 1, upper arrowhead lane 1).
Lung contains a second prominent immunoreactive species,
but in this case it is a di¡use band of apparent Mr 63 kDa
(Fig. 1, arrowheads lane 7), which is distinct from both gp65
and the 61 kDa species detected in liver. Di¡use higher Mr
species are detected in other tissues such as stomach and testis
(Fig. 1, lanes 4 and 6).
In order to con¢rm that, as for gp65 and gp55 from brain,
the immunoreactive species detected in other tissues contain
high mannose oligosaccharide residues, Con A binding experi-
ments were carried out using solubilised membrane proteins
from liver, muscle, lung and brain. Liver and muscle show
patterns of immunoreactivity common to several tissues, while
the lung and brain patterns are unique among the tissues
tested. A Western blot of samples of the starting material
and the eluted Con A binding glycoproteins is shown in
Fig. 2. The results show that the 61 and 44 kDa immuno-
reactive species detected in liver and muscle are enriched in
the Con A binding material (Fig. 2, lanes 2 and 4 respectively)
compared to the starting material (Fig. 2, lanes 1 and 3
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Fig. 1. An antibody speci¢c for gp65 and gp55, mab SMgp65, rec-
ognises immunoreactive species in a range of tissues. A Western
blot of samples of solubilised membrane proteins prepared from a
range of tissues was immunodeveloped with mab SMgp65. The sam-
ples in order of loading from lane 1 to 9 were prepared from liver
(Li), kidney (Ki), skeletal muscle (Mu), stomach (St), spleen (Sp),
testis (Te), lung (Lu), heart (He) and brain (Br). Lower arrowheads
indicate an immunoreactive band of apparent Mr 44 kDa. Upper
arrowhead lane 1 and arrowheads lane 7 indicate immunoreactive
bands of apparent Mr 61 and 63 kDa respectively. Protein loading:
20 Wg/track.
Fig. 2. Immunoreactive species recognised by mab SMgp65 in liver,
muscle, lung and brain bind to Con A. A Western blot of detergent
solubilised membrane protein (Mem.) and Con A binding material
(Con A) from liver, muscle, lung and brain was immunodeveloped
with mab SMgp65. Odd and even lanes represent solubilised mem-
brane protein and Con A binding material from the same tissue.
Thus lanes 1, 3, 5 and 7 are solubilised membrane protein and lanes
2, 4, 6 and 8 are Con A binding material from liver, muscle, lung
and brain. Arrowheads lanes 5 and 6 denote a 63 kDa immunoreac-
tive species. Protein loading was 20 Wg/lane for membrane proteins.
The loading of Con A binding material represented the amount ex-
tracted from 40 Wg of membrane protein.
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respectively) as is the 63 kDa species present in lung (Fig. 2,
arrowheads lanes 5 and 6 respectively). As expected the brain
Con A binding fraction is enriched in gp65 and gp55 com-
pared to the starting material (Fig. 2, lanes 7 and 8 respec-
tively). The apparent increase in the Mr of the immunoreac-
tive glycoprotein species in the Con A binding compared to
the starting material is due to the large amounts of Con A
present in the samples which interferes with electrophoretic
migration. The Con A is shed by the agarose beads during
solubilisation of the binding proteins for SDS polyacrylamide
gel electrophoresis.
In order to provide evidence that the immunoreactive spe-
cies detected in tissues other than brain arise from gp55 sam-
ples of membrane proteins prepared from liver, kidney, lung
and brain were enzymically deglycosylated using endo-F/
PNGase F. This enzyme combination removes all N-linked
oligosaccharides from glycoproteins. The results for brain
show prominent bands of Mr 40 and 28 kDa in the deglyco-
sylated compared to the non-deglycosylated sample (Fig. 3,
lanes 7 and 8 respectively). These correspond to the previously
established Mr values for deglycosylated gp65 and gp55 from
brain [2]. The endo-F/PNGase F treated samples from liver,
lung and kidney (lanes 1, 3 and 5 respectively) all show prom-
inent deglycosylated bands of Mr 28 kDa, i.e. identical to the
Mr of deglycosylated gp55, but no 40 kDa gp65 derived im-
munoreactive product.
Our data lead us to conclude that the novel immunoreactive
species detected by mab SMgp65 in tissues other than brain
are derived from gp55, but not gp65. This is con¢rmed by
immunodevelopment of a Western blot of control and di-
gested samples of brain, liver, kidney and lung with a⁄nity
puri¢ed gp65-speci¢c antiserum (Fig. 4). As expected the anti-
serum recognises gp65 and its deglycosylated 40 kDa product
in the control digested (Fig. 4, lane 1) and endo-F/PNGase F
treated (Fig. 4, lane 2) samples of brain. No immunoreactive
bands were detected in the other tissues. As the sequence of
gp55 is common to both glycoproteins it is not possible to
repeat the experiment with an antibody speci¢c for this mol-
ecule.
The detection of at least two (and in some cases more)
immunoreactive bands derived from gp55 in many of the tis-
sues examined raises the possibility that the lower Mr species
artefactually arises from the higher due to the action of en-
dogenous glycosidases during sample preparation. In order to
rapidly denature such enzymes and so discount this possibility
samples of adult brain, liver, kidney and lung were immersed
in boiling bu¡er for 5 min immediately following removal and
prior to homogenisation. The results (not shown) con¢rm the
same pattern of immunoreactive bands are present in both
boiled and control samples.
The present results suggest that the pattern of gp55 glyco-
sylation is dependent upon the cell type expressing the glyco-
protein. To further investigate this and test if the same would
be true for gp65, the glycoforms present in HEK293 cells
stably transfected with cDNAs encoding either gp65 or gp55
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Fig. 5. Glycoforms detected in gp65 and gp55 transfected HEK cells
di¡er from those detected in brain. A Western blot of control and
endo-F/PNGase F digested samples of HEK cells transfected with
gp65 or gp55 immunodeveloped with mab SMgp65. Lanes 1 and 2
show control and endo-F/PNGase F digested samples of gp55 trans-
fected cells. Lanes 3 and 4 show control and endo-F/PNGase F di-
gested samples of gp65 transfected cells. Protein loading: 20 Wg/
track.
Fig. 4. An antibody speci¢c for gp65 does not recognise immuno-
reactive species in liver, kidney and lung. A Western blot of control
and endo-F/PNGase F digested samples immunodeveloped with
antiserum speci¢c for gp65 prepared as described in Section 2.
Lanes 1, 3, 5 and 7 are control and lanes 2, 4, 6 and 8 are endo-F/
PNGase F digested samples from brain, liver, kidney and lung.
Gp65 immunoreactivity is detected only in control and endo-F/
PNGase F digested samples from brain. Protein loading: 20 Wg/
track.
Fig. 3. Deglycosylation of immunoreactive species recognised by
mab SMgp65 in liver, kidney, lung and brain with endo-F/PNGase
F. Western blot of samples of solubilised membrane proteins from
liver, lung, kidney and brain incubated in the presence or absence
of endo-F/PNGase F. Control and endo-F/PNGase F digested sam-
ples from the same tissue are in adjacent lanes. Thus lanes 2, 4, 6
and 8 are control digested samples and lanes 1, 3, 5 and 7 are
endo-F/PNGase F digested samples from liver, lung, kidney and
brain. Enzyme indicates the combination of endo-F/PNGase F. Pro-
tein loading: liver and kidney 40 Wg/track, lung 15 Wg/track, brain
5 Wg/track.
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were investigated. We have previously shown that control
HEK293 cells are not immunoreactive. The pattern of immu-
noreactive species recognised by mab SMgp65 in control and
deglycosylated samples of the gp65 and gp55 transfected cells
is shown in Fig. 5. Two major bands of Mr 61 and 44 kDa
were detected in the gp55 transfected cells (Fig. 5, lane 1). As
expected a single 28 kDa immunoreactive species only was
observed following endo-F/PNGase F digestion (Fig. 5, lane
2). The higher molecular mass minor immunoreactive compo-
nents almost certainly represent low levels of partially degly-
cosylated intermediates as we have previously demonstrated
for brain [2]. The gp65 transfected cells also expressed two
immunoreactive species, but in this case of apparent Mr 67
and 59 kDa (Fig. 5, lane 3) which yielded the expected 40 kDa
peptide product following endo-F/PNGase F treatment (Fig.
5, lane 4). Thus the pattern of glycosylation of both of these
Ig superfamily members is clearly dependent upon the cell
type in which they are expressed.
4. Discussion
The current results demonstrate that unlike gp65, gp55 gly-
coforms are expressed in a wide range of tissues. A number of
these, notably the 55 kDa brain glycoform and the 63 kDa
species detected in lung, have a restricted tissue distribution
and may indeed be tissue speci¢c. Other glycoforms are much
more widely distributed, notably the 44 kDa species which
was detected in all tissues examined. Variation in glycoforms
is well established for many glycoproteins (for reviews see
[8,9]). Perhaps the best characterised example is the Thy-1
molecule which is expressed in brain and thymus. This small-
est member of the Ig superfamily is N-glycosylated at three
sites giving rise to a number of glycoforms [8]. Strikingly there
is no overlap between brain and thymus glycoforms.
Signi¢cantly tissue speci¢c glycosylation has been reported
for the chick blood-brain barrier glycoprotein neurothelin/
(HT7/5A11 antigen) and its mouse homologue, basigin
[10,11]. These molecules are the Ig superfamily members
which share closest sequence homology (40^44%) with gp55.
In retina 5A11/HT7 glycoforms with Mrs of 69 and 45.5 kDa
are observed [10]. Immunoreactive bands of Mr 46^50 kDa
are detected in erythrocytes, liver and kidney. The Mr of the
45.5^50 kDa molecular species from all tissue was lowered to
32 kDa following enzymic deglycosylation con¢rming that the
di¡erences in molecular mass are associated with di¡erences in
glycosylation. The apparent Mr of the 69 kDa species from
retina was lowered to only 46 kDa following deglycosylation.
This raises the possibility that the 69 kDa species, like gp65,
has three Ig domains rather than the two Ig domains de-
scribed for the lower Mr 5A11/HT7 species. Indeed the cor-
responding exon is contained in the basigin gene [4,12]. Fa-
dool and Linser [10] attributed much of the observed
di¡erence in Mr between 5A11/HT7 glycoforms to di¡erences
in sialic acid content. However, the apparent Mrs of gp65 and
gp55 from brain are lowered by only 2^3 kDa following di-
gestion with neuraminidase [2].
The pattern of glycosylation of gp65 and gp55 is at least in
part determined by the cell type in which they are expressed.
This is best illustrated by the HEK293 cells transfected with
cDNAs encoding gp55 and gp65. The gp55 glycoforms ex-
pressed in the transfected cells are of identical Mr to those
found in several other tissues including kidney and liver.
Strikingly two gp65 glycoforms of Mr 67 and 59 kDa are
expressed in the transfected cells, compared to the single dif-
fuse 65 kDa species observed in brain. This plausibly suggests
that both gp65 and gp55 may have a similar pattern of gly-
cosylation in the transfected cells which is distinct from
that of brain. The patterns of glycosylation in brain do
show speci¢c trends which di¡er from other tissues. In partic-
ular there is a dominance of anionic oligosaccharides and by
complex glycans, often fucosylated [9]. The brain glycoforms
of gp65 and gp55 have a similar gross carbohydrate compo-
sition, although 2-D gel electrophoresis shows di¡erences in
microheterogeneity between gp65 and gp55 consistent with
some di¡erences in precise oligosaccharide structure. In this
context gp65 contains no additional N-glycosylation sites to
gp55.
Variation in the oligosaccharide structure of glycoproteins
has been shown to have important functional consequences,
for example, in regulation of cell surface events such as rec-
ognition and adhesion phenomena [13,14]. Thus homophilic
adhesion between NCAMs is regulated in part by the content
of polysialic acid chains [15,16]. Cis interaction between
NCAM and L1 is inhibited by castanospermine, an alkaloid
which interferes with processing of high mannose to complex
and hybrid oligosaccharides [17]. The HNK-1 sulphated glu-
curonic acid glycan is implicated in cell-substrate adhesion via
interactions with the G2 domain of laminin K chain [13,18].
Modi¢cation of the terminal sugar residues of oligosacchar-
ides present on glycoproteins by surface galactosyl transfer-
ases is suggested to alter neurite outgrowth [19]. Changes in
fucosylation have been implicated in learning in chicks [20]
and in long-term potentiation in the rat [21]. Thus tissue var-
iation in the oligosaccharide composition of gp55 may mod-
ulate its function.
The functions of gp65 and gp55 are not yet known. The
available evidence suggests a role as positive or negative ef-
fectors of cell recognition and adhesion is most likely. The
localisation of gp65 to the processes and terminals of subsets
of neurones suggests that it may have an adhesive function at
these loci whereas the widespread distribution of gp55 is con-
sistent with an adhesive role between a wide range of cell
types. Experiments designed to investigate the functions of
these molecules will have to take into account the possible
e¡ect of variations in glycosylation.
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